Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta).
Journal
Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440
Informations de publication
Date de publication:
03 Dec 2021
03 Dec 2021
Historique:
entrez:
1
12
2021
pubmed:
2
12
2021
medline:
2
12
2021
Statut:
ppublish
Résumé
Vaccines are instrumental and indispensable in the fight against the COVID-19 pandemic. Several recent SARS-CoV-2 variants are more transmissible and evade infection- or vaccine-induced protection. We constructed live attenuated vaccine candidates by large-scale recoding of the SARS-CoV-2 genome and showed that the lead candidate, designated sCPD9, protects Syrian hamsters from a challenge with ancestral virus. Here, we assessed immunogenicity and protective efficacy of sCPD9 in the Roborovski dwarf hamster, a nontransgenic rodent species that is highly susceptible to SARS-CoV-2 and severe COVID-19–like disease. We show that a single intranasal vaccination with sCPD9 elicited strong cross-neutralizing antibody responses against four current SARS-CoV-2 variants of concern, B.1.1.7 (Alpha), B.1.351 (Beta), B.1.1.28.1 (Gamma), and B.1.617.2 (Delta). The sCPD9 vaccine offered complete protection from COVID-19–like disease caused by the ancestral SARS-CoV-2 variant B.1 and the two variants of concern B.1.1.7 and B.1.351.
Identifiants
pubmed: 34851677
doi: 10.1126/sciadv.abk0172
pmc: PMC8635430
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
eabk0172Références
Science. 2021 Aug 13;373(6556):818-823
pubmed: 34016740
Cell Rep. 2020 Dec 8;33(10):108488
pubmed: 33271063
Nat Med. 2021 May;27(5):917-924
pubmed: 33772244
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Science. 2008 Jun 27;320(5884):1784-7
pubmed: 18583614
Nat Med. 2021 Jul;27(7):1230-1238
pubmed: 34035535
N Engl J Med. 2021 May 20;384(20):1899-1909
pubmed: 33951374
JAMA. 2021 Mar 2;325(9):821-822
pubmed: 33507218
Cell. 2021 May 27;184(11):2939-2954.e9
pubmed: 33852911
PLoS Pathog. 2018 Jan 29;14(1):e1006857
pubmed: 29377958
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
J Gen Virol. 2018 Dec;99(12):1705-1716
pubmed: 30113295
Vaccines (Basel). 2021 Apr 07;9(4):
pubmed: 33916924
BMJ. 2021 Aug 2;374:n1933
pubmed: 34340962
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Lancet Reg Health Am. 2021 Sep;1:100025
pubmed: 34386791
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
Cell Rep. 2021 Aug 3;36(5):109493
pubmed: 34320400
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Proc Natl Acad Sci U S A. 1989 May;86(10):3699-703
pubmed: 2657727
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Am J Respir Cell Mol Biol. 2020 Dec;63(6):856-859
pubmed: 32897757
Cell. 2021 Aug 5;184(16):4220-4236.e13
pubmed: 34242578
Cell Rep. 2020 Apr 28;31(4):107586
pubmed: 32348767
Nat Med. 2021 Mar;27(3):440-446
pubmed: 33531709
Viruses. 2020 Jul 20;12(7):
pubmed: 32698441
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
Nature. 2021 May;593(7857):130-135
pubmed: 33684923